ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,961 to 4,980 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
H01: Medication vs Total H01: Medication + CABG: H01: Cardiac Procedure: Heart Transplant3 of 602

0 of 610

0.5 points

-0.2 to 1.5

1,212NCT00023595

Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease

Total H01: Medication + CABG vs H01: Medication: H01: Cardiovascular Mortality (Defined as Sudden Death or Death Attributed to Recurrent MI, HF, a Cardiovascular Procedure, Stroke, or Other Cardiovascular Etiology).247 of 610

297 of 602

-8.8 points

-14.4 to -3.2

1,212NCT00023595

Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease

H01: Medication vs Total H01: Medication + CABG: H01: Heart Failure Hospitalization169 of 602

127 of 610

7.3 points

2.4 to 12.1

1,212NCT00023595

Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease

H01: Medication vs Total H01: Medication + CABG: H01: All-cause Mortality or Revascularization (CABG or PCI)478 of 602

388 of 610

15.8 points

10.7 to 20.7

1,212NCT00023595

Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease

H01: Medication vs Total H01: Medication + CABG: H01: All-cause Mortality or Heart-failure Hospitalization450 of 602

404 of 610

8.5 points

3.4 to 13.6

1,212NCT00023595

Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease

H01: Medication vs Total H01: Medication + CABG: H01: Cardiac Procedure: Heart Transplant4 of 602

1 of 610

0.5 points

-0.4 to 1.5

1,212NCT00023595

Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease

H01: Medication vs Total H01: Medication + CABG: H01: Cardiac Procedure: Left Ventricular Assist Device (LVAD)2 of 602

4 of 610

-0.3 points

-1.4 to 0.6

1,212NCT00023595

Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease

Cervarix Group vs Engerix Group: Number of Subjects Reporting Medically Significant Conditions (MSCs) Including Potential Immune Mediated Diseases (pIMDs)5 of 606

7 of 606

-0.3 points

-1.6 to 0.9

1,212NCT01277042

Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)

Cervarix Group vs Engerix Group: serious adverse events3 of 606

3 of 606

0.0 points

-1.0 to 1.0

1,212NCT01277042

Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)

CD5789 (Trifarotene) 50µg/g Cream vs Placebo Cream: serious adverse events2 of 602

4 of 610

-0.3 points

-1.4 to 0.6

1,212NCT02556788

Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris

V212 [Including High Antigen Lot] vs Placebo: deaths from any cause136 of 657

107 of 554

1.4 points

-3.2 to 5.9

1,211NCT01229267

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001)

V212 [Including High Antigen Lot] vs Placebo: serious adverse events420 of 657

374 of 554

-3.6 points

-8.9 to 1.8

1,211NCT01229267

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001)

Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Identifying Clinic Visits as BP Care Burden at Six Months196 of 632

149 of 578

5.2 points

0.1 to 10.3

1,210NCT02996565

Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure

Women 16-26 Years of Age vs Women 27-45 Years of Age: serious adverse events6 of 570

8 of 640

-0.2 points

-1.5 to 1.2

1,210NCT03158220

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Aflibercept vs Placebo: serious adverse events331 of 611

184 of 598

23.4 points

17.9 to 28.7

1,209NCT00519285

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer

CD5789 (Trifarotene) 50μg/g Cream vs Placebo Cream: Investigator Global Assessment (IGA) Success Rate at Week 12180 of 612

116 of 596

9.9 points

5.1 to 14.7

1,208NCT02566369

Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris

CD5789 (Trifarotene) 50μg/g Cream vs Placebo Cream: serious adverse events4 of 612

2 of 596

0.3 points

-0.6 to 1.4

1,208NCT02566369

Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris

CD5789 (Trifarotene) 50µg/g Cream vs Placebo Cream: Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear)255 of 598

157 of 609

16.9 points

11.5 to 22.1

1,207NCT02556788

Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris

H5N1 Adjuvanted Group vs H5N1 Un-adjuvanted Group: Number of Subjects With Serious Adverse Events (SAEs).7 of 961

0 of 245

0.7 points

-0.9 to 1.5

1,206NCT00449670

Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults

H5N1 Adjuvanted Group vs H5N1 Un-adjuvanted Group: Number of Subjects With Any Unsolicited Adverse Events (AEs)308 of 961

75 of 245

1.4 points

-5.2 to 7.7

1,206NCT00449670

Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=249"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=249

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00023595-bd1f5251",
        "title": "H01: Medication vs Total H01: Medication + CABG: H01: Cardiac Procedure: Heart Transplant",
        "summary": "3 of 602 against 0 of 610; risk difference 0.5 points, 95% interval -0.2 to 1.5; NCT00023595, Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",
        "record": "/library/comparisons/NCT00023595-bd1f5251",
        "nct_id": "NCT00023595",
        "kind": "outcome",
        "participants": 1212,
        "risk_difference": {
          "value": 0.0049833887043189366,
          "lower": -0.002085475722215995,
          "upper": 0.014548062023536262
        },
        "group_1": "3 of 602",
        "group_2": "0 of 610",
        "difference": "0.5 points",
        "interval": "-0.2 to 1.5",
        "trial_title": "Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease"
      },
      {
        "id": "NCT00023595-bf4b7d98",
        "title": "Total H01: Medication + CABG vs H01: Medication: H01: Cardiovascular Mortality (Defined as Sudden Death or Death Attributed to Recurrent MI, HF, a Cardiovascular Procedure, Stroke, or Other Cardiovascular Etiology).",
        "summary": "247 of 610 against 297 of 602; risk difference -8.8 points, 95% interval -14.4 to -3.2; NCT00023595, Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",
        "record": "/library/comparisons/NCT00023595-bf4b7d98",
        "nct_id": "NCT00023595",
        "kind": "outcome",
        "participants": 1212,
        "risk_difference": {
          "value": -0.0884374489406895,
          "lower": -0.1436704333303432,
          "upper": -0.03243379291546418
        },
        "group_1": "247 of 610",
        "group_2": "297 of 602",
        "difference": "-8.8 points",
        "interval": "-14.4 to -3.2",
        "trial_title": "Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=250",
  "request_id": "PCRsbOkcfSyPFCH3"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?